Reduce the global burden of RSV infection
Learning Hub
Trusted, evidence-based resources for GPs and midwives. Explore modules on RSV, vaccination, and hMPV to close knowledge gaps and improve practice.
Patient Network
Our latest posts
Upcoming:
ReSViNET Webinar
part of the PIPELINE Project
Informed consent in pregnant women – infants
• Date: October 8th, 2026
• Time: 16:00 – 17:00 CEST
Previous:
ReSViNET webinar
part of the CLARITY Project
The genetic basis of virus infection-induced asthma
How can we understand why RSV leads to more severe or longer-lasting consequences in some people than in others?
In this webinar, we explored how large biobanks integrate retrospective medical records, genetic data, and stored blood samples to:
• Study host susceptibility to pathogens
• Identify biological pathways involved in infection response
• Understand how these mechanisms may contribute to chronic lung disease
Article PATH
One step closer to protection: Setting the stage for maternal RSV vaccine introduction
With new global recommendations in place, countries are poised to take next steps toward introducing maternal RSV vaccines and safeguarding infants from a major health threat.
Article Gavi and partners
Gavi and partners commence design of RSV maternal vaccine programme
17 – 20 february 2026 – Rome, Italy
Thank you for joining us at RSVVW’26!
RSV Papers
WHO position paper on immunization to protect infants against RSV disease
Recommendations on the use of maternal respiratory syncytial virus vaccines and long-acting RSV monoclonal antibodies (mAbs) to prevent severe RSV disease in infants were issued by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization in September 2024 and endorsed by WHO thereafter.
Global call for access to RSV vaccination for all children worldwide
Together with 44 organisations worldwide, we’re proud to call for global action on RSV.
RSV causes 33 million cases and over 100,000 child deaths every year, 97% in the world’s poorest countries.
A new Call to Action published in The Lancet today urges Gavi to support equitable access to RSV prevention tools in low- and middle-income countries, where the disease burden is greatest and vaccine access remains limited.
PROMISE
The ReSViNET Foundation and ReSViNET’s Patient Network were partners in IMI’s PROMISE study. The aim of PROMISE was to significantly advance our understanding of RSV to aid in the design of public health strategies as well as the development and use of vaccines and therapeutics in both children and older people. It built on the work of IMI’s RESCEU project, which delivered significant insights and resources on RSV.
Innovative tool
The RSV Chatbot!
We’re excited to introduce an innovative tool: the RSV chatbot. Created by the ReSViNET Foundation in collaboration with UMC Utrecht researchers. This 24/7 chatbot offers reliable, expert-verified information on RSV in almost every language. Access it anytime on the ReSViNET website or via WhatsApp.
RSV Chatbot
Up-to-date expertise, anytime, anywhere.
Paper of the Month:
March 2026
RSV vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. They conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023–2024.
Authors: Alisa Kachikis et al.
PIPELINE RSV Study
The PIPELINE‑RSV International Trial has reached a key milestone with the first site activation approval at St George’s University Hospitals NHS Foundation Trust in London. This marks the start of recruitment for both the site and the UK arm of the study.
Led by Dr. Eva Galiza, the site will enroll pregnant women into the adaptive platform trial evaluating two licensed RSV prevention options: the maternal RSV vaccine given during pregnancy and the monoclonal antibody Nirsevimab given to infants.
The UK study arm will examine whether combining maternal vaccination with Nirsevimab at 4 months provides stronger, longer‑lasting protection against RSV than maternal vaccination alone. RSV is a major cause of respiratory illness in infants, with about one in fifteen requiring hospital care in their first year.
A global health challenge
Every year, Respiratory Syncytial Virus (RSV) affects more than 33 million children under 5 years worldwide. It is one of our most significant global healthcare challenges, not only in infants, but also in older adults. ReSViNET is the first official RSV foundation and aims to provide a platform for global collaborations to raise awareness about RSV infection and stimulate the development of RSV prevention and treatment.
Global RSV surveillance
The RSV Dashboard
We have developed the first-ever global RSV surveillance dashboard!
ReSViNET Foundation, in collaboration with AstraZeneca, is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. ReSViNET provides the first online and free dashboard about RSV. The dashboard simplifies tracking changes in RSV seasonality globally and includes at least 20 countries that are representative of different geographic regions from both hemispheres.
Our organization
Connecting research and society
The ReSViNET Foundation is the first and leading global non-profit organisation fully committed to reducing the global burden of the Respiratory Syncytial Virus (RSV).
We collaborate with various stakeholders, such as researchers, the health sector, governments, international statutory bodies, non-profit organisations and the general public to raise awareness about RSV. Together, we address the challenges of prevention and treatment.